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Objective(s): Several lines of evidence showed that minocycline possesses antioxidant and anti-
inflammatory properties. This study aimed to demonstrate the effects of minocycline in rats subjected 
to chronic constriction injury (CCI). 
Materials and Methods: In this study four groups (n = 6–8) of rats were used as follows: Sham, CCI, CCI 
+ minocycline (MIN) 10 mg/Kg (IP) and CCI + MIN 30 mg/Kg (IP). On days 3, 7, 14, and 21 post-surgery 
hot-plate, acetone, and von Frey tests were carried out. Finally, Motor Nerve Conduction Velocity 
Evaluation (MNCV) assessment was performed and spinal cords were harvested in order to measure 
tissue concentrations of TNF_α, IL-1β, Glutathione peroxidase (GPx), Superoxide dismutase (SOD) and 
Malondialdehyde (MDA). Extent of perineural inflammation and damage around the sciatic nerve was 
histopathologically evaluated. 
Results: Our results demonstrated that CCI significantly caused hyperalgesia and allodynia twenty-one 
days after CCI. MIN attenuated heat hyperalgesia, cold and mechanical allodynia and MNCV in animals. 
MIN also decreased the levels of TNF_α and IL-1β. Antioxidative enzymes (SOD, MDA, and GPx) were 
restored following MIN treatment. Our findings showed that MIN decreased perineural inflammation 
around the sciatic nerve. According to the results, the neuropathic pain reduced in the CCI hyperalgesia 
model using 30 mg/kg of minocycline. 
Conclusion: It is suggested that antinociceptive effects of minocycline might be mediated through the 
inhibition of inflammatory response and attenuation of oxidative stress.  
 
 
Article history: 
Received: Jun 12, 2017 
Accepted: Sep 28, 2017 
 
 
Keywords:  
Chronic constriction- 
Injury 
Inflammatory response 
Minocycline 
Neuropathic pain 
Oxidative stress 
Rat 
 
 
 
 
 
►Please cite this article as: 
Abbaszadeh A, Darabi S, Hasanvand A, Amini-khoei H, Abbasnezhad A, Choghakhori R, Aaliehpour A. Minocycline through attenuation of 
oxidative stress and inflammatory response reduces the neuropathic pain in a rat model of chronic constriction injury. Iran J Basic Med 
Sci 2018; 21:138-144. doi: 10.22038/IJBMS.2017.24248.6053 
 
 
 
Introduction 
Neuropathic pain (NP) is caused by several factors 
with impairment in nerve function. The pathophysiology 
of pain is relatively complex and involves the central and 
peripheral mechanisms. Alteration in the ion channel 
expression, neurotransmitter release, and pain 
pathways are involved in the pathophysiology of pain 
(1). NP consists of unpleasant sensations of burning, 
tingling, and increased sensitivity towards the 
hyperalgesia and allodynia (2). When the tissue is 
destroyed, an inflammatory reaction leads to the 
activation of the pain pathway (3).  
 
 
It is known that both hyperalgesia and allodynia 
coexist in both, the inflammatory and neuropathic pain 
(4). 
It has been well-documented that oxidative stress 
contributes to the pathophysiology of NP (5). In this 
regard, it is demonstrated that reduction in antioxidant 
protection, increase in oxidant generation, and loss of 
the capacity of repair from oxidative damage are 
involved in the NP consequence of oxidative stress (6).  
Minocycline is a broad-spectrum and long-acting 
antibiotic and also possesses anti-inflammatory and 
antioxidant effects (7, 8). It has been shown that 
minocycline acts as an inhibitor of microglial activation  
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(9) and also exerts neuroprotective effects in the 
experimental model of brain ischemia (10, 11). Previous 
studies have demonstrated that systemic injection of 
minocycline reduces the microglia activation and 
consequently diminishes the production of the 
inflammatory cytokines in the CNS (12, 13). Ample 
evidence showed that minocycline protects neurons 
against impairment due to stroke and traumatic injury 
(14, 15). It is well-accepted that minocycline possesses 
antioxidant property (16, 17). Some researchers suggest 
that the neuroprotective effects of minocycline are via 
mitochondrial action. In this regard, minocycline executes 
its neuroprotective effect via inhibition (direct) of MPT 
(mitochondrial permeability transition) pores 
cytochrome c release (18, 19). 
The aim of this study is to investigate the protective 
effect of different doses of minocycline on NP considering 
behavioral tests and antioxidant and anti-inflammatory 
properties in a rat model of chronic constriction injury. 
 
Materials and Methods 
Animals  
Thirty-two rats (male adult Sprague–Dawley) weighing 
200–250 g were purchased and housed in standard 
conditions (4 rats per cage) i.e. temperature 23±2 °C, 
humidity of approximately 50%, and 12-hr light/dark 
cycle (9 a.m. - 9 p.m. lights on) (20). The animals had free 
availability of water and food.  
 
Experimental design 
Minocycline (Sigma, St. Louis, MO, USA) was 
suspended in distilled water. Pentobarbital sodium 
(Sigma-Aldrich, St. Louis, MO, USA) was used for 
anesthesia. Animals were divided randomly into four 
experimental groups (n= 8 rats per group): 1: Sham-
operated (Sh), 2: CCI saline-treated (CCI), 3: CCI + 
Minocycline (MIN) 10 mg/kg intraperitoneal (IP), 4: CCI 
+ MIN 30 mg/kg (IP). Minocycline was injected one day 
before surgery and continued daily for 21 days post-
ligation. Doses of minocycline were chosen based on 
previously published study (21-23). Regarding these 
studies, we performed a pilot study and selected two 
doses of 10 and 30 mg/kg of minocycline.  
 
Surgery 
To induce sciatic nerve injury the CCI model of NP 
was performed (24). The surgical procedure was 
performed under pentobarbital Na (60 mg/kg) 
anesthesia. The left sciatic nerve was exposed and three 
ligations were put around the nerve. The space between 
two adjacent ligatures was 1 mm. In sham rats, the same 
surgical procedure was done, but not ligated.  
 
Thermal stimulation tests 
Behavioral tests were recorded on days 3, 7, 14, and 
21 after ligation. The experiments were started with the  
heat hyperalgesia stimulation test and terminated with 
mechanical allodynia. 120 min was considered as the 
interval time between two tests. 
 
Heat hyperalgesia stimulation (hot-plate test):  
Eddy’s hot-plate, as an index of thermal hyperalgesia, 
was used to study the thermal nociceptive threshold by 
keeping the temperature at 52.5 ± 3.0 °C. Animals were 
placed on the hot-plate and withdrawal latency, with 
respect to the licking of the hind paw, was recorded in 
seconds. The cut-off time of 15 sec was maintained (25). 
 
Cold allodynia (acetone test): 
In cold allodynia test, the rat's hind paw was placed 
over a wire mesh and 100 μl of acetone was sprayed 
onto its surface without touching the skin. The response 
to acetone was noted in 20 sec and was scored according 
to the criteria described by Kukkar and Singh as follows: 
0: no reflex; 1: quick stamp, flick or withdrawal of the 
paw; 2: repeated flicking or prolonged withdrawal; and 
3: repeated flicking with licking of the paw. In this test, 
acetone was used three times, every 5 min. The score 
range was defined from zero to nine (26).  
 
Mechanical Allodynia (von Frey Test) 
Briefly, the rats were placed in a cage (20 * 20 * 10 
cm) whose floor was made of meshed metal wire. A 
chain of von Frey filament stimuli was delivered in an 
arising order of forces to the central section of the 
plantar hind paw skin (three times repeatedly). 
Stimulation of the plantar hind paw due to common 
locomotors behavior was ignored. The sequence of 
stimuli was stopped when the rat responded with 
immediate flinching or licking of the hind paw skin (27).  
 
Motor Nerve Conduction Velocity Evaluation (MNCV) 
MNCV recordings were carried out 3 weeks after CCI. 
On day 21, animals were anesthetized by intraperitoneal 
injection of pentobarbital Na (60 mg/kg, Sigma-Aldrich). 
To expose the sciatic nerve, the skin and muscles were 
disjointed layer by layer. MNCV was assessed by 
inducing a compound action potential from the 
stimulating electrode at the proximal end and recording 
from the recording electrode at the distal end of the 
injury site (28) 
 
Enzyme-linked immunosorbent assays (ELISA) 
TNF_α, IL-1β, GPx, SOD, and MDA levels were 
assessed in the spinal cord samples. For this purpose, the 
spinal cord between the L4-L5 segments was isolated 
immediately after behavioral measurements. 
Homogenate tissues were prepared with 0.9% saline 
using glass homogenate and then centrifuged at 2500 
r/min for 10 min. Supernatant (10%,w/v) was used for 
ELISA assay (29, 30). 
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Figure 1. The effect of minocycline administration on CCI-induced heat 
hyperalgesia, assessed using the hot-plate test. Rats were treated with 
vehicle or minocycline at doses of 10 and 30 mg/kg once daily for a 
period of 21 days. The data were shown as mean ± SEM. ** P< 0.01 vs 
Sham, ***P< 0.001 vs Sham, #P< 0.05 vs CCI, ## P< 0.01 vs CCI, and ### 
P< 0.001 vs CCI 
 
Histologic evaluation  
On day 21, sciatic nerves were dissected. Histological 
studies were performed according to the described 
protocol. For histological examination, samples of sciatic 
nerve were cut into segments of 5-micrometer sections 
and stained with hematoxylin and eosin. All samples 
were analyzed for perineural inflammation and 
according to protocol-defined guidelines (31). 
 
Statistical analysis 
Data were expressed as mean ± SEM. Two-way 
analysis of variance (ANOVA) followed by Tukey's post 
hoc test using the Graph-pad prism software (ver. 6) was 
done for data analysis. A P-value˂0.05 was considered 
statistically significant.  
 
Results  
Minocycline decreased heat hyperalgesia  
Results obtained from the hot-plate test (Figure 1) 
showed that CCI significantly decreased the pain 
threshold in days 3, 7, 14, and 21 (P<0.001, for all days) 
after the operation. Following treatment with minocycline 
10 mg/kg pain threshold significantly increased when 
compared with the CCI group in days 14 (P<0.05) and 21 
(P<0.01) post-surgery. Our findings from administration 
of minocycline 30 mg/kg showed that pain sensitivity 
decreased in days 3 (P<0.05), 7 (P<0.01), 14 (P<0.001), 
and 21 (P<0.001) post operation in comparison with CCI 
counterparts. Furthermore, minocycline at dose 30 
mg/kg in days 7 and 14 post induction of NP decreased 
sensitivity in comparison with minocycline 10 mg/kg 
(P<0.05).  
 
Minocycline decreased cold allodynia scores 
Results obtained from acetone test (Figure 2) 
revealed that induction of CCI significantly increased 
allodynia scores in days 3 (P<0.05), 7, 14, and 21 after 
surgery in comparison with sham groups (P<0.001). 
Post hoc analysis showed that administration of 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The effects of minocycline administration on CCI- induced 
cold allodynia assessed using the acetone test. Rats were treated with 
vehicle or minocycline at doses of 10 and 30 mg/kg once daily for a 
period of 21 days. The data were shown as mean ± SEM. *** P< 0.001 vs 
Sham, # P< 0.05 vs CCI, and ### P< 0.001 vs CCI 
 
minocycline (10 and 30 mg/kg) significantly reduced 
allodynia scores when compared with CCI counterparts 
in days 7 (P<0.05), 14 and 21 post operation (P<0.001).  
 
Minocycline increased latency to mechanical 
allodynia 
Our results from von ferry test (Figure 3) 
demonstrated that CCI operation significantly increased 
sensitivity to mechanical allodynia in days 7 (P>0.05), 14 
(P>0.001), and 21 (P>0.001) post induction when 
compared with related sham counterparts. Administration 
of minocycline at a dose of 30 mg/kg increased latency 
to mechanical stimulation at day 21 post-CCI operation 
in comparison with CCI groups (P<0.05). 
 
Effect of minocycline on MNCV 
Neural conduction was reduced in the CCI group 
relative to the sham group at the 21st day after injury 
(P<0.01), indicating that neural conduction was 
diminished (Figure 4). MNCV values began to recover by 
3 weeks in 10 mg/kg and 30 mg/kg of minocycline 
treatment groups (P< 0.05, P< 0.1, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The effects of minocycline administration on CCI-induced 
mechanical allodynia assessed using the von Frey test. Rats were 
treated with vehicle or minocycline at doses of 10 and 30 mg/kg once 
daily for a period of 21 days. The data were shown as mean ± SEM. ** 
P< 0.01 vs Sham, *** P< 0.001 vs Sham, and ### P< 0.001 vs CCI 
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Figure 4. The effects of minocycline administration on MNCV in the 
sciatic nerve. Rats were treated with vehicle or minocycline at doses of 
10 and 30 mg/kg once daily for a period of 21 days. The data were 
shown as mean ± SEM; *** P< 0.001 vs Sham, # P< 0.05 vs CCI, and ### 
P< 0.001 vs CCI 
 
Minocycline decreased levels of inflammatory 
cytokines 
Our findings revealed that levels of TNF-α and IL-1β 
significantly increased in the 21st day post-surgery in 
comparison with their sham counterparts (P<0.001 for 
both).  Moreover, treatment with dose 30 mg/kg of 
minocycline decreased the concentration of IL-1β when 
compared with the CCI group (P<0.05). Furthermore, 
minocycline at doses 10 and 30 mg/kg significantly 
decreased the level of TNF-α in comparison with the CCI 
group (P<0.001 for both) (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The effects of minocycline administration on IL-1β and TNF-
α in the spinal nerve. Rats were treated with vehicle or minocycline at 
doses of 10 and 30 mg/kg once daily for a period of 21 days. The data 
were shown as mean ± SEM; *** P< 0.001 vs Sham, # P< 0.05 vs CCI, and 
### P< 0.001 vs CCI 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The effects of minocycline administration on MDA, SOD, and 
GPx levels in the spinal nerve. Rats were treated with vehicle or 
minocycline at doses of 10 and 30 mg/kg once daily for a period of 21 
days. The data were shown as mean ± SEM, *** P< 0.001 vs Sham, # P< 
0.05 vs CCI, ## P< 0.01 vs CCI, and ### P< 0.001 vs CCI 
 
Effect of minocycline on oxidative markers 
Measurement of concentration of markers relevant 
to the oxidative/anti-oxidative state using ELISA (Figure 
6) showed that CCI led to increase in the level of MDA 
and decrease in the levels of SOD as well as GPx (P<0.001 
for both). Minocycline (10 and 30 mg/kg) significantly 
decreased the levels of MDA (P<0.001 for both), 
increased the levels of SOD (P<0.05 and P<0.01, 
respectively), and glutamine peroxidase (P<0.001 for 
both) compared to the CCI group.  
 
Minocycline decreased perineural inflammation 
around the sciatic nerve 
Figure 7 shows that there are normal structural                  
in the sciatic nerve of sham animals. Moreover, histological 
results from CCI groups showed that there was extensive 
perineural inflammation around the sciatic nerve 
(score=3). However, administration of minocycline (30 
mg/kg) attenuated CCI induced inflammation ratio 
around the sciatic nerve (score = 1).  Furthermore, nerve 
injury was not detected in the sciatic nerve of any group 
(Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Histological and morphological studies in the sciatic nerve at 
21 days after CCI induction. In untreated CCI rats, the sciatic nerve has 
diffuse areas of moderate to marked edema/cellular infiltrate. In the 
MIN-treated (30 mg/kg) CCI rats, the finding is small focal areas of mild 
edema and/or cellular infiltrate  
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Discussion 
CCI model is a valid model used to induce NP (32). In 
this study, we demonstrated that chronic constriction 
injury induced NP within twenty-one days after the 
operation. Our results showed that treatment with 
minocycline (10 and 30 mg/kg) for a 21 day period 
significantly improved the behavioral changes induced 
by CCI, including heat hyperalgesia, cold and mechanical 
allodynia, and MNCV. Furthermore, minocycline 
attenuated inflammatory cytokines as well as oxidative 
stress markers. Also, we observed that administration of 
minocycline significantly decreased perineural 
inflammation around the sciatic nerve. Our findings 
demonstrated that optimum result were obtained from 
30 mg/kg of minocycline. 
It has been determined that minocycline exerted 
antioxidant effects and mitigated the glial cells damage 
due to oxidative/nitrosative stress (33, 34). Conversely, 
in another study, it was found that minocycline 
possessed some beneficial effects on the oxidative stress 
in diabetic animals (35). The anti-inflammatory and 
neuroprotective properties of minocycline have been 
studied. In this regards, it is determined that 
minocycline is effective in Parkinson's disease (36), 
Alzheimer’s disease (37), and also in a genetic mouse 
model of retinitis pigmentosa (38). El-Shimy et al. 
showed that minocycline reduced the inflammatory 
response and exerted protective effects in nerve cells 
against nerve toxins (39).  
Minocycline reduced the activity of the MAPK 
pathway in microglia (40). It is found that minocycline 
acted as an anti-apoptotic agent (41) and protected 
neurons from caspase activation through decreased Ca+ 
absorption and decreasing the release of cytochrome-C 
from mitochondria (42). Previous studies declared that 
minocycline indirectly regulated the increase of the anti-
apoptotic factors, e.g. BCL2 (43) and also inhibited the 
apoptosis proteins (44). Minocycline inhibits the 
activation of microglia and reduces the expression of the 
inflammatory mediators (45). It has been shown that 
minocycline is effective in chronic disorders caused by 
diabetes, and three week treatment with minocycline 
improved the diabetic neuropathy (46). It is important 
to state that long-term treatment with minocycline is 
completely safe (47). Compared with normal rats and 
sciatic nerve injury rats, TNF-α upregulation was in 
nerve cells and detectable at the damage site in the 
standard model of NP (48). It has been shown that the 
levels of TNF-α increased in the locus coeruleus and 
hippocampus (49). Upregulation of proinflammatory 
cytokines such as IL-1Β, has been reported in the spinal 
cord and ipsilateral ganglia following nerve injury (50). 
In addition, it was reported that in the animal models of 
NP, the receptors of IL-1β have been induced by TNF-α 
receptor 1 (51). In the present study, minocycline 
reduced the levels of TNF-α and IL-1β, which may have 
partial roles in the efficacy of this agent in prevention of 
NP. Elevated levels of ROS induce persistent pain and 
related pain behaviors and also, it has been detected in 
ipsilateral superficial laminae (I-III) of the spinal cord 
(52). Preclinical evidence supports the fact that 
oxidative stress could enhance NP and induced 
hyperalgesia in the injured peripheral nerve and/or 
spinal cord (53).  Our findings suggest that minocycline 
could be at least in part through the modulation of 
oxidative stress mitigated NP in the CCI model. 
 
Conclusion  
The present findings support that minocycline 
possessed anti-inflammatory and antioxidant effects 
in the chronic constriction injury induced NP and 
could prevent and at least delay the development of 
hypersensitivity in the CCI model. 
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